n.a. (ANX)

0.73
AMEX
Prev Close 0.73
Day Low/High 0.00 / 0.00
52 Wk Low/High 0.00 / 0.00
Exchange AMEX
Div & Yield N.A. (N.A)

Latest News

Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial

Mast Therapeutics Initiates Sub-Study Within Phase 3 EPIC Trial

Sub-study will investigate effects of MST-188 on tissue oxygenation in sickle cell disease patients experiencing a vaso-occlusive crisis

Mast Therapeutics Announces New Data Supporting MST-188 In Sickle Cell Disease

Mast Therapeutics Announces New Data Supporting MST-188 In Sickle Cell Disease

MST-188 decreased a marker of inflammation and red blood cell aggregation (50% reduction relative to control)

ADVENTRX Announces Corporate Name Change To

ADVENTRX Announces Corporate Name Change To "Mast Therapeutics, Inc."; Ticker Symbol Change To "MSTX"

Name and ticker symbol changes effective March 11, 2013

Adventrx To Develop ANX-188 For Complications Of Arterial Disease

Adventrx To Develop ANX-188 For Complications Of Arterial Disease

- Seeking orphan drug designation in acute limb ischemia (ALI)

ADVENTRX Reviews Data Supporting Development Of ANX-188 In New Indications

ADVENTRX Reviews Data Supporting Development Of ANX-188 In New Indications

- Platform includes over 100 pharmacology studies, 15 clinical studies and 2,500 patient exposures

ADVENTRX To Initiate Phase 3 Study Of ANX-188

ADVENTRX To Initiate Phase 3 Study Of ANX-188

- Study Title: EPIC (Evaluation of Purified poloxamer In Children in crisis)

ADVENTRX Announces Launch Of New Corporate Website

ADVENTRX Announces Launch Of New Corporate Website

Establishes Social Media Presence

ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188

ADVENTRX Announces Details Of The Phase 3 Study Of ANX-188

-Conference Call Scheduled for Today at 4:30 p.m. (ET)/1:30 p.m. (PT)

ADVENTRX Announces Conference Call To Review Protocol For Phase 3 Clinical Study Of ANX-188

ADVENTRX Announces Conference Call To Review Protocol For Phase 3 Clinical Study Of ANX-188

Conference Call Scheduled for 4:30pm ET / 1:30pm PT on Thursday, October 25

ADVENTRX Pharmaceuticals To Present At 1st Annual Sickle Cell Disease Therapeutics Conference

ADVENTRX Pharmaceuticals To Present At 1st Annual Sickle Cell Disease Therapeutics Conference

Conference Will Include Clinical-Stage Company Presentations & Sickle Cell Disease Expert Panels

4 Biotech Stocks Under $10 Moving Higher

4 Biotech Stocks Under $10 Moving Higher

Regardless of the reason behind it, when a stock makes a large-percentage move, it is often just the start of a new major trend -- a trend that can lead to huge profits.